Could a transplant drug tame thyroid eye disease?
NCT ID NCT04936854
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study compares sirolimus (an oral drug) to standard steroid infusions for treating active thyroid eye disease, a condition causing bulging eyes and discomfort. Researchers aim to see if sirolimus works better and causes fewer side effects. The trial involves 60 adults with moderate-to-severe disease and lasts 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sirolimus (oral tablet)
What this could lead to
If successful, sirolimus could offer a more effective and safer treatment option for active thyroid eye disease, reducing inflammation and eye bulging with fewer side effects than steroids.
What could go wrong
This is a small Phase 2 trial with only 60 participants, so results may not apply to everyone. Sirolimus may not work better than steroids and could have its own side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Ophthalmology Haukeland University Hospital
RECRUITINGBergen, Hordaland, 5021, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••